Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection.

Expert review of gastroenterology & hepatology - 1 Jan 2015

Chayama Kazuaki, Mitsui Fukiko, Hayes C Nelson

Abstract excerpt

Treatment of chronic hepatitis C virus infection has substantially improved following the advent of direct acting antiviral (DAA) agents. Although the first generation protease inhibitors telaprevir and boceprevir improved sustained viral response (SVR) rates, adverse events remain severe and immature termination of the therapy is frequent; however, intensive dose modification has improved completion and SVR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Resistance, Viral
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Molecular Targeted Therapy

Share to Protease Inhibitors

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 25220206
DOI: 10.1586/17474124.2015.960394

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection.PMID 25220206Read ↗

Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.Semantic proximity Read ↗

Key points for the management of hepatitis C in the era of pan-genotypic direct-acting antiviral therapySemantic proximity Read ↗

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.Semantic proximity Read ↗

New hepatitis C therapies: the toolbox, strategies, and challenges.Semantic proximity Read ↗

The hepatitis C revolution part 1: antiviral treatment options.Semantic proximity Read ↗

A review of standard and newer treatment strategies in hepatitis C.Semantic proximity Read ↗

Interferon free therapy with direct acting antivirals for HCV.Semantic proximity Read ↗

Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.Semantic proximity Read ↗

Direct-acting antivirals: the endgame for hepatitis C?Semantic proximity Read ↗

Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection.Semantic proximity Read ↗

Interferon-free regimens for hepatitis C: combine and conquer.Semantic proximity Read ↗

Future perspectives: towards interferon-free regimens for HCV.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.